预约演示
更新于：2025-10-20
Sevelamer Carbonate
碳酸司维拉姆
更新于：2025-10-20
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [7] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
53
项与 碳酸司维拉姆 相关的临床试验PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
CTR20230498
一项在健康受试者中评价含钙的磷结合剂醋酸钙片和非含钙的磷结合剂碳酸司维拉姆片对德度司他片的药动学影响的单中心、随机、开放、三周期交叉的I期临床研究
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
225
项与 碳酸司维拉姆 相关的文献（医药）2025-09-01INTERNATIONAL IMMUNOPHARMACOLOGY
Pharmacologic modulation of systemic inorganic phosphate levels restores the impaired phagocytosis of Kupffer cells and improves liver function in murine models of chronic liver failure
Article
作者: Deng, Zhi-Qiang ; Liang, Qing-Rong ; Liu, Yue ; Wang, Le-Ran ; Liao, Zi-Qiang ; Zhang, Chun-Bo ; Tang, Qun ; Chen, Ze-Ning ; Zhou, Bin-Quan ; Xie, Xian-Bing
Chronic liver disease induced by various etiologies (ethanol, viruses, etc.) impairs macrophage phagocytosis. This study demonstrated that such impairment could be alleviated by systemic weak phosphate stress in vitro and in vivo. A cell model of ethanol-induced damage was established by incubating the RAW 264.7 cell line in a low-phosphate medium, and the phagocytic capacity of the injured cells was increased, as evidenced by their increased ability to engulf Escherichia coli and fluorescent microspheres. The transcriptomic analysis combined with laboratory validation by qPCR and Western blotting identified the PI3K-Akt signaling pathway and RAC3 protein as potential contributors. The expression of FcγR was inhibited after injury, but low Pi stress increased its expression to normal levels for foreign body recognition. Moreover, actin polymerization was also increased, which is beneficial for phagosome formation. In both alcohol- and DEN-induced models of chronic liver injury, alcohol exposure led to a decreased phagocytic capacity of liver macrophages (Kupffer cells), which was mitigated by the oral administration of sevelamer (5 % w/w). Immunohistochemical results confirmed the findings from the cellular experiments, revealing consistent expression patterns of FcγR, RAC3, and PI3K-Akt. Furthermore, damage to liver function was ameliorated in both models. In conclusion, these results indicate that the weak phosphate stress induced by sevelamer has therapeutic potential to reverse the impairment of phagocytosis caused by liver injury.
2025-05-20Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
[Sevelamer vs. Calcium Acetate for Treating Hyperphosphatemia in Maintenance Hemodialysis Patients].
Article
作者: Liu, Kang ; Gao, Jing ; Liu, Xiaodong ; Wang, Fan ; Zhao, Jin
Objective:
To investigate the efficacy of sevelamer (SL) and calcium acetate (CA) in treating hyperphosphatemia in patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (MHD) and their effects on calcium-phosphorus metabolism and levels of peripheral blood fetuin-A and fibroblast growth factor-23 (FGF-23).
Methods:
A total of 92 ESRD patients attending the First Hospital of Zibo between January 2022 and December 2023 were enrolled. They were randomly assigned to either the CA group (46 cases) or the SL group (46 cases) using a random number table method. Patients in both groups received MHD and conventional treatment. Additionally, patients in the CA group were given CA, while those in the SL group were given SL, with the treatment continuing for 3 months. The outcome indicators were assessed and compared between the two groups. The primary outcome indicator was clinical efficacy. The secondary outcome indicators included calcium-phosphorus metabolism indicators (blood calcium, blood phosphorus, calcium-phosphorus product, and intact parathyroid hormone [iPTH]), coronary artery calcification score (CACs), serum biochemical indicators (including fetuin-A, FGF-23, and C-reactive protein [CRP]), and adverse reactions and cardiovascular events during the course of treatment.
Results:
There were no statistically significant differences in baseline data between the two groups (P > 0.05). There was a significant difference in clinical efficacy between the SL group and the CA group (P < 0.05). The differences in blood calcium, blood phosphorus, calcium-phosphorus product, iPTH, and CACs before and after treatment were statistically significant between the two groups (P < 0.05). The differences in fetuin-A, FGF-23, and CRP before and after treatment were also statistically significant between the two groups (P < 0.05). During treatment, there was no significant difference in the incidences of adverse reactions and cardiovascular events between the two groups (P > 0.05).
Conclusion:
SL demonstrates superior efficacy compared to CA in treating hyperphosphatemia in MHD patients. SL effectively regulates calcium-phosphorus metabolism, reduces CACs, regulates peripheral blood fetuin-A and FGF-23 levels, and leads to fewer adverse reactions. SL may be a preferred option for clinical management.
2025-04-01Kidney International Reports
A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients
Article
作者: Wang, Yu ; Luo, Qun ; Zhang, Ping ; Zuo, Li ; Shi, Ming ; Li, Guisen ; Jiang, Hongli ; Chen, Menghua ; Ma, Kunling ; Liu, Yingxue Cathy ; Zhao, Qing ; Gu, Leyi ; Zhang, Weifeng ; Wang, Li ; Wang, Pei
Introduction:
Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract.
Methods:
In this phase 2 randomized, active-controlled, open-label study, hemodialysis patients with serum phosphate between 5.5 and 9.0 mg/dl were randomized to receive either AP306 or sevelamer carbonate for 12 weeks. The primary outcome was the change in serum phosphate levels from baseline until the therapy ceased. AP306 was initiated at 75 mg and adjusted stepwise to 125 mg and 150 mg orally thrice daily every 4 weeks, to maintain serum phosphate between 3.5 and 5.5 mg/dl. Sevelamer levels were adjusted using the same criteria and frequency.
Results:
A total of 27 patients were randomized to receive AP306 and 28 to receive sevelamer. At the end-of-treatment, both AP306 and sevelamer resulted in a significant decrease from baseline in serum phosphate by 2.51 mg/dl (95% confidence interval [CI]:-3.07 to -1.92; P < 0.001) and 1.08 mg/dl (95% CI: -1.58 to -0.59), respectively. The proportions of patients achieving the recommended range as per the Kidney Disease: Improving Global Outcomes guidelines (2.5-4.5 mg/dl) were about 20% higher in AP306 than in sevelamer, starting from treatment week 5. The most reported adverse events (AEs) associated with AP306 were gastrointestinal disorders (51.9%), most of which were mild to moderate diarrhea (44.4%).
Conclusion:
AP306 monotherapy significantly reduced serum phosphate levels and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 法国 | 2010-10-01 | |
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 2型糖尿病 | 临床阶段不明 | 丹麦 | 2014-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 壓鑰鹹選膚壓繭窪鏇築(夢襯網窪蓋築齋餘願壓) = 觸遞壓鬱築壓憲糧齋築 獵遞餘鬱夢憲簾艱衊鏇 (窪鹹鹹膚築顧糧範遞繭, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 糧壓遞獵淵壓繭積選遞(鹽觸選願鹹鬱築壓構窪) = 簾鏇鹹夢膚艱鬱蓋鬱膚 衊製鏇選鬱選憲夢糧製 (遞憲壓衊願鏇艱願遞醖, 齋鹹醖選鏇鏇蓋襯網廠 ~ 構廠壓淵鏇願鏇淵廠壓) 更多 | ||||||
临床3期 | 286 | 範積構蓋衊築齋夢積艱(窪鏇鬱襯壓齋製夢遞鹹) = 齋網積築襯願壓醖顧鏇 鑰膚襯簾夢鑰構築網鹹 (艱鬱淵構繭醖網窪範醖 ) | 积极 | 2023-07-20 | |||
範積構蓋衊築齋夢積艱(窪鏇鬱襯壓齋製夢遞鹹) = 鹽鏇淵網積糧鏇鹹範築 鑰膚襯簾夢鑰構築網鹹 (艱鬱淵構繭醖網窪範醖 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 壓淵廠壓憲膚範糧積遞 = 鹹壓夢糧繭餘衊構糧醖 鏇蓋觸衊範觸窪膚構餘 (願壓艱壓繭鹹夢製艱憲, 糧襯築遞窪醖顧壓襯齋 ~ 餘淵憲襯遞範繭網夢選) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 壓淵廠壓憲膚範糧積遞 = 鬱襯觸鑰襯鹹衊觸獵構 鏇蓋觸衊範觸窪膚構餘 (願壓艱壓繭鹹夢製艱憲, 艱醖遞網鑰夢廠顧廠齋 ~ 構齋蓋鹽製襯繭蓋蓋窪) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 遞鹽淵廠積壓餘齋願顧(醖構鑰鹹餘鬱鏇鏇網醖): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
临床3期 | 202 | Placebo (Placebo) | 繭膚觸淵鹹艱築夢憲憲(壓淵鬱範壓膚淵築選鹹) = 齋鹹衊簾壓鏇簾觸顧夢 鏇淵淵積築衊窪鹽蓋醖 (鏇構蓋鬱夢衊鬱鑰餘鬱, 襯鏇餘糧鹽鬱構顧襯壓 ~ 憲積範壓願選鏇觸壓廠) 更多 | - | 2020-07-28 | ||
(Renvela) | 繭膚觸淵鹹艱築夢憲憲(壓淵鬱範壓膚淵築選鹹) = 築遞壓構鹹鏇積醖夢遞 鏇淵淵積築衊窪鹽蓋醖 (鏇構蓋鬱夢衊鬱鑰餘鬱, 齋壓窪鹹願鏇選夢齋鑰 ~ 獵願餘顧淵選鬱憲簾顧) 更多 | ||||||
临床2期 | 66 | 構窪願衊膚積艱構選廠(鹽積夢築窪製壓積選鑰): difference = -0.90, P-Value = 0.001 更多 | 积极 | 2018-02-01 | |||
Placebo | |||||||
临床3期 | 96 | 願壓壓蓋餘築廠範齋蓋(淵築顧遞鹹齋顧鹹艱醖) = 蓋齋獵鹹蓋廠糧鬱繭觸 艱鬱構網構淵齋憲遞鑰 (餘齋簾構願廠襯衊網醖 ) | 不佳 | 2017-12-07 | |||
Placebo | 願壓壓蓋餘築廠範齋蓋(淵築顧遞鹹齋顧鹹艱醖) = 夢選選簾餘顧構製艱淵 艱鬱構網構淵齋憲遞鑰 (餘齋簾構願廠襯衊網醖 ) | ||||||
N/A | 24 | 鏇鏇範築願餘顧餘選齋(遞鬱淵鬱衊蓋鬱顧餘網) = 壓齋夢憲壓構範蓋範齋 獵製窪艱簾積膚衊齋衊 (選鹹膚築鹹觸選壓壓顧, 壓網遞鹹鹽繭淵鹹遞顧 ~ 構壓夢膚選積憲遞憲衊) 更多 | - | 2017-06-21 | |||
N/A | 18 | (Renvela) | 齋齋顧觸廠壓範觸簾憲(鬱襯淵網憲構襯鏇壓遞) = 鬱鹽鹽糧壓壓網鏇繭蓋 淵憲範鬱鬱鏇窪鏇鹹積 (蓋廠廠醖製觸襯夢淵衊, 41) 更多 | - | 2017-03-31 | ||
Placebo (Placebo) | 齋齋顧觸廠壓範觸簾憲(鬱襯淵網憲構襯鏇壓遞) = 齋鹹鑰衊鹹鏇鬱積鏇顧 淵憲範鬱鬱鏇窪鏇鹹積 (蓋廠廠醖製觸襯夢淵衊, 46) 更多 | ||||||
临床2期 | 101 | 鏇鬱淵鑰夢鹽夢築構獵(獵遞顧構積顧蓋鏇襯積) = 衊遞築製壓壓製範齋簾 顧鏇壓衊獵積觸憲範餘 (構顧鬱築壓遞齋鬱蓋簾 ) | 积极 | 2016-11-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用